Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Olaparib (AZD2281): Advancing PARP Inhibition for BRCA-De...
2025-09-30
Explore the unique mechanistic insights and advanced applications of Olaparib (AZD2281) as a selective PARP-1/2 inhibitor for BRCA-deficient cancer research. This article goes beyond standard reviews by integrating new findings on platinum resistance and DNA damage response assays for targeted therapy innovation.
-
SR-202 (PPAR Antagonist): Deconstructing Macrophage Polar...
2025-09-29
Explore the advanced role of SR-202, a selective PPARγ antagonist, in dissecting macrophage polarization and immunometabolic signaling. This article offers novel insights into PPAR-dependent adipocyte differentiation inhibition, uniquely bridging metabolic and immune research.
-
Bortezomib (PS-341): Unraveling Proteasome Inhibition and...
2025-09-28
Explore the scientific frontier of Bortezomib (PS-341), a reversible proteasome inhibitor, and its unique impact on mitochondrial proteostasis and programmed cell death mechanisms. This article provides a comprehensive analysis linking 20S proteasome inhibition to metabolic regulation and advanced therapeutic strategies in multiple myeloma and mantle cell lymphoma research.
-
10058-F4: Advanced Applications of a c-Myc-Max Dimerizati...
2025-09-27
Explore the unique mechanisms and research applications of 10058-F4, a potent c-Myc-Max dimerization inhibitor. Discover how this small-molecule tool advances apoptosis research and cancer biology beyond conventional approaches.
-
Cy5-UTP:
2025-09-26
Explore how Cy5-UTP (Cyanine 5-uridine triphosphate) revolutionizes in vitro transcription RNA labeling, enabling advanced studies of phase separation and molecular interactions in modern molecular biology. Uncover unique mechanistic insights and applications not found in prior guides.
-
DMXAA (Vadimezan, AS-1404): Redefining Tumor Vasculature ...
2025-09-25
Discover the unique anti-cancer mechanisms of DMXAA (Vadimezan, AS-1404), a vascular disrupting agent and DT-diaphorase inhibitor. This article offers a novel systems biology perspective on DMXAA’s role in tumor microenvironment modulation and advanced research applications in cancer biology.
-
Cyclopamine: Advanced Insights into Smoothened Receptor I...
2025-09-24
Explore the multifaceted role of Cyclopamine as a Hedgehog signaling inhibitor, focusing on its nuanced mechanisms, unique teratogenicity models, and translational applications in cancer research. This article offers deeper comparative analysis and practical guidance for scientists utilizing Cyclopamine in cutting-edge studies.
-
BGJ398 as a Selective FGFR Inhibitor: Novel Insights for ...
2025-09-23
This article examines BGJ398 (NVP-BGJ398) as a highly selective FGFR inhibitor, highlighting its mechanistic utility in oncology research and its value in dissecting FGFR-driven malignancies. Emphasis is placed on its molecular selectivity, experimental applications, and new perspectives on FGFR signaling pathways.
-
The aldehyde reductase AKR A and aldose reductase
2025-03-03
The aldehyde reductase (AKR1A1) and aldose reductase (AKR1B1) belong to aldo-ketoreductase (AKR) superfamily catalyzing the reduction of corresponding aldehydes and ketones involved. Both the closely related enzymes AKR1A1 and AKR1B1 have 65% structural similarity and differ only at the active site.
-
tyrosine kinase receptor Flavonoids protein interactions stu
2025-03-03
Flavonoids-protein interactions studies play a substantial part in the hunt for novel molecules which are to interact with a selected disease-relevant target [35]. The mode of potential interaction gives information about the flavonoid effectiveness and selectivity. Lately, possible target molecules
-
In addition we aimed to
2025-03-03
In addition, we aimed to examine the possible role of adiponectin in modulating changes in IR. It was observed that there was a simultaneous decline in expression of IR and AdipoR1 proteins in the ovary of PCOS-mice as compared to the control ovary. Further, a strong correlation was found between ch
-
br Results br Discussion The actin cytoskeleton is
2025-03-03
Results Discussion The Cyanidin Chloride cytoskeleton is a highly attractive target for many bacterial toxins, owing to its role in activation and locomotion of immune cells, secretion of humoral response factors, and maintenance of protective barriers at the cellular (sub-membrane cytoskelet
-
Nevertheless though the LO pathway dictates the
2025-03-03
Nevertheless, though the 5-LO pathway dictates the production of lipid mediators with opposite roles in the immune reactions, like LTs and LXA4 [32], our results seemed to corroborate others that pointed to LTB4 as an outstanding mediator involved in persistent and chronic inflammatory skin diseases
-
All scientific data over the years points
2025-03-03
All scientific data over the years points that 5α-reductase inhibitors undoubtedly are an effective treatment for BPH and associated LUTS, having a favorable risk-benefit profile. In contrast, although some studies indicated positive results, there is still no consensus about their use in BPH or PC
-
CAY10499 sale Physiological total plasma LPA levels
2025-03-03
Physiological total plasma LPA levels are normally less than 1μM in healthy subjects. LPA levels have been reported to be increased in malignant effusions or plasma in cancer patients [20]. In addition, increasing ATX activity detected in healthy pregnant women in the third trimester of pregnancy ex